MX2017007191A - Procedimiento de produccion de cristales de derivado de diazabiciclooctano y preparacion liofilizada estable. - Google Patents

Procedimiento de produccion de cristales de derivado de diazabiciclooctano y preparacion liofilizada estable.

Info

Publication number
MX2017007191A
MX2017007191A MX2017007191A MX2017007191A MX2017007191A MX 2017007191 A MX2017007191 A MX 2017007191A MX 2017007191 A MX2017007191 A MX 2017007191A MX 2017007191 A MX2017007191 A MX 2017007191A MX 2017007191 A MX2017007191 A MX 2017007191A
Authority
MX
Mexico
Prior art keywords
compound
stable lyophilized
lyophilized preparation
producing crystals
diazabicyclooctane derivative
Prior art date
Application number
MX2017007191A
Other languages
English (en)
Inventor
Ogawa Takaya
Yokoyama Takuya
Furuyama Shusuke
Ichiki Masato
Fushihara Kenichi
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of MX2017007191A publication Critical patent/MX2017007191A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Los objetos de la presente invención consisten en proporcionar un procedimiento para producir cristales del compuesto (I) con facilidad en una escala industrial y una composición liofilizada estable de compuesto (I); se halló que sometiendo una solución acuosa que contiene el compuesto (I) y una sal inorgánica tal como cloruro de sodio a liofilización da como resultado una composición liofilizada con buena estabilidad de almacenamiento, en donde el compuesto (I) es cristalino y también que los cristales del compuesto (I) se pueden obtener de dicha solución acuosa sin liofilización. (ver Fórmula).
MX2017007191A 2014-12-05 2015-12-04 Procedimiento de produccion de cristales de derivado de diazabiciclooctano y preparacion liofilizada estable. MX2017007191A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014246425 2014-12-05
PCT/JP2015/084094 WO2016088863A1 (ja) 2014-12-05 2015-12-04 ジアザビシクロオクタン誘導体の結晶及び安定な凍結乾燥製剤の製造法

Publications (1)

Publication Number Publication Date
MX2017007191A true MX2017007191A (es) 2017-08-28

Family

ID=56091802

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007191A MX2017007191A (es) 2014-12-05 2015-12-04 Procedimiento de produccion de cristales de derivado de diazabiciclooctano y preparacion liofilizada estable.

Country Status (18)

Country Link
US (2) US10294224B2 (es)
EP (1) EP3228620B1 (es)
JP (1) JP6779787B2 (es)
KR (1) KR102555657B1 (es)
CN (1) CN107001366B (es)
AR (1) AR102915A1 (es)
AU (1) AU2015355970B2 (es)
BR (1) BR112017010445B8 (es)
CA (1) CA2969192C (es)
ES (1) ES2821826T3 (es)
IL (1) IL252691B (es)
MX (1) MX2017007191A (es)
MY (1) MY190283A (es)
RU (1) RU2732129C2 (es)
SG (1) SG11201704576SA (es)
TW (1) TWI691499B (es)
WO (1) WO2016088863A1 (es)
ZA (1) ZA201704063B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201605368UA (en) 2012-05-30 2016-08-30 Meiji Seika Pharma Co Ltd NOVEL β-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME
CN111153903A (zh) 2013-10-08 2020-05-15 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法和应用以及医药组合物
JP6779787B2 (ja) * 2014-12-05 2020-11-04 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ジアザビシクロオクタン誘導体の結晶及び安定な凍結乾燥製剤の製造法
KR20200091395A (ko) 2017-09-27 2020-07-30 페도라 파마슈티칼스 인코포레이티드 디아자비시클로옥탄 유도체의 결정형 및 그의 제조 방법
US10584123B2 (en) 2017-09-27 2020-03-10 Fedora Pharmaceuticals Inc. Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof
JP7179058B2 (ja) * 2017-09-27 2022-11-28 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ジアザビシクロオクタン誘導体の剤形およびその生産プロセス
JP6375463B1 (ja) * 2018-02-28 2018-08-15 日本曹達株式会社 ビス（フルオロスルホニル）アミドアルカリ金属塩粉末の製造方法
CN110314163A (zh) * 2018-03-30 2019-10-11 杭州森泽医药科技有限公司 一种拉氧头孢钠药物组合物及应用
JP2022094481A (ja) * 2020-12-15 2022-06-27 大阪瓦斯株式会社 ヒドロキシアルカン酸結晶の製造方法及びヒドロキシアルカン酸の結晶多形体

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1589317A (en) * 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用１１１１５１５２１３９１９９東京都中央区京橋２丁目３番１３号
JPS6019759A (ja) 1983-07-15 1985-01-31 Nippon Soda Co Ltd ホルムアミドオキシム誘導体その製造方法及び農園芸用殺菌剤
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
PL157979B1 (pl) 1989-02-14 1992-07-31 Sprezyna z dwoma stanami równowagi trwalej PL PL
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (es) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
AU700545B2 (en) * 1994-05-02 1999-01-07 Shionogi & Co., Ltd. Crystal of pyrrolidylthiocarbapenem derivative, lyophilized preparation containing said crystal, and process for producing the same
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶，該結晶を含む凍結乾燥製剤，およびその製造方法
DE19531874C1 (de) 1995-08-30 1996-10-02 Daimler Benz Ag Seitenwandbaugruppe für eine Kraftfahrzeugkarosserie
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
DK2666774T3 (en) 2008-01-18 2015-03-23 Merck Sharp & Dohme Beta-lactamase INHIBITORS
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
PL2657234T3 (pl) 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Optycznie czynna pochodna diazabicyklooktanowa i sposób jej wytwarzania
MX361020B (es) 2011-06-17 2018-11-26 Pfizer Anti Infectives Ab Procesos para preparar compuestos heterociclicos, incluida trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo [3,2,1]octano-2-carboxam ida y sales de la misma.
US8822450B2 (en) 2011-08-27 2014-09-02 Wockhardt Ltd. 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
CA2845108C (en) 2011-08-30 2015-06-16 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections
ES2640520T3 (es) 2011-09-13 2017-11-03 Wockhardt Limited Compuestos que contienen nitrógeno y su uso
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) * 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
SG10201605368UA (en) 2012-05-30 2016-08-30 Meiji Seika Pharma Co Ltd NOVEL β-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME
US10000491B2 (en) * 2013-09-24 2018-06-19 Meiji Seika Pharma Co., Ltd. Process for producing diazabicyclooctane derivative and intermediate thereof
CN111153903A (zh) 2013-10-08 2020-05-15 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法和应用以及医药组合物
JP6779787B2 (ja) 2014-12-05 2020-11-04 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ジアザビシクロオクタン誘導体の結晶及び安定な凍結乾燥製剤の製造法

Also Published As

Publication number Publication date
BR112017010445B1 (pt) 2024-01-30
RU2017123112A3 (es) 2019-06-25
IL252691B (en) 2020-08-31
ZA201704063B (en) 2021-10-27
RU2732129C2 (ru) 2020-09-11
ES2821826T3 (es) 2021-04-27
CN107001366A (zh) 2017-08-01
US10294224B2 (en) 2019-05-21
BR112017010445A2 (pt) 2017-12-26
MY190283A (en) 2022-04-12
AU2015355970B2 (en) 2020-05-21
AR102915A1 (es) 2017-04-05
RU2017123112A (ru) 2019-01-09
KR20170094272A (ko) 2017-08-17
WO2016088863A1 (ja) 2016-06-09
JP6779787B2 (ja) 2020-11-04
CA2969192C (en) 2023-02-28
AU2015355970A1 (en) 2017-06-15
IL252691A0 (en) 2017-08-31
JPWO2016088863A1 (ja) 2017-09-14
CN107001366B (zh) 2020-08-28
TW201629062A (zh) 2016-08-16
KR102555657B1 (ko) 2023-07-18
SG11201704576SA (en) 2017-07-28
US11117895B2 (en) 2021-09-14
NZ732214A (en) 2021-10-29
EP3228620B1 (en) 2020-09-02
US20170327499A1 (en) 2017-11-16
EP3228620A4 (en) 2018-05-02
CA2969192A1 (en) 2016-06-09
US20190202831A1 (en) 2019-07-04
EP3228620A1 (en) 2017-10-11
BR112017010445B8 (pt) 2024-02-27
TWI691499B (zh) 2020-04-21

Similar Documents

Publication Publication Date Title
MX2017007191A (es) Procedimiento de produccion de cristales de derivado de diazabiciclooctano y preparacion liofilizada estable.
PH12017501016B1 (en) Triazolopyrimidine compounds and uses thereof
EA201790722A1 (ru) КОМПОЗИЦИЯ С НИЗКИМ pH, СОДЕРЖАЩАЯ КОНКРЕТНЫЕ КОНСЕРВАЦИОННЫЕ СИСТЕМЫ
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
MX2016002368A (es) Compuestos de sulfonamida heterociclica sustituida utiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1).
MX2021014663A (es) Il-23a y tnf-alfa orientados y compuesto y sus usos.
TW201613603A (en) Pharmaceutical preparation
EA201691363A1 (ru) Стабилизированные силикатные композиции и их применение в качестве антиперспирантных композиций
EA201692288A1 (ru) Способ получения фосфорсодержащих циангидринов
MA39824A (fr) Composés azole amido-substitués
CY1124838T1 (el) Αλας παραγωγου κεφαλοσπορινης, κρυσταλλικη, στερεη μορφη αυτου και μεθοδος παραγωγης αυτου
CU20130001A7 (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen
BR112016017087A8 (pt) forma cristalina alfa do composto monobenzoato a e seu método de preparação e composição farmacêutica compreendendo-a
EA201791329A1 (ru) Новые кристаллические формы мононатриевой соли форамсульфурона
EA201692045A1 (ru) Производное фенантролинфосфоновой кислоты и способ его получения и применения
CY1120402T1 (el) Νεο αλας ιμβαμπραδινης και μεθοδος παρασκευης αυτου
MX2021015198A (es) Peptidos toxicos activados artificialmente.
MX2017004770A (es) Formas solidas del clorhidrato de nilotinib.
IN2013CH04330A (es)
WO2015001565A3 (en) "an improved process for the preparation of 3-aryloxy-3- phenylpropylamine and salt thereof"
IN2013MU02843A (es)
UA88452U (ru) Способ аммонизации раствора хлористого натрия
TW201613927A (en) Method for preparation of substituted imidazopyridazines
IN2013CH04519A (es)

Legal Events

Date Code Title Description
FG Grant or registration